BIRAC invites proposals under R&D for Guar-Gum before 31st August 2019
The Primary scope of the program is to support R & D gaps of guar and its derivatives for the long-term profitability and sustainability of guar industry in India.
Boehringer Ingelheim acquires AMAL Therapeutics to enrich cancer immunology portfolio
Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.